Chad Swanson
Equibles does not estimate personal net worth.
About Chad Swanson
Prothena Corp Public Ltd Co reported in an 8-K filed October 2, 2026 that Chad Swanson resigned as Chief Development Officer, effective October 9, 2026. Chad Swanson has spoken on 2 earnings calls across 1 company, most recently for Prothena Corp Public Ltd Co on February 19, 2026. The companies whose calls Chad Swanson spoke on are classified in the Healthcare sector.
“On October 2, 2026, Chad J. Swanson, Ph.D., Chief Development Officer of Prothena Corporation plc (the "Company") notified the Company that he is resigning from the Company effective October 9, 2026.”
Chad Swanson on recent calls
“Presonuzumab is a humanized IgG1 monoclonal antibody designed to selectively bind aggregated forms of alpha-synuclein to reduce neuronal toxicity and slow disease progression of Parkinson's disease by blocking further accumulation and propagation of these toxic aggregates.”
“I'd like to start my discussion with a review of Batamib, our anti-amyloid treatment for AL amyloidosis. We are nearing the completion of our confirmatory Phase III Affirm AL clinical trial.”
Affiliation history
-
Prothena Corp Public Ltd Co (PRTA)
Source not stated
Start not stated–2026-10-09